What finasteride is and its approved use in the United States
Finasteride is an oral prescription medication that belongs to a class of drugs called 5-alpha-reductase inhibitors. In the United States it has two distinct approved indications that use different doses. For androgenetic alopecia, commonly called male pattern hair loss, the approved dose is 1 mg once daily. For benign prostatic hyperplasia, a prostate condition, the approved dose is 5 mg once daily.
These two indications are separate, and so are the doses and the branded products that carry them. Finasteride 1 mg is sold under the brand name Propecia, while the 5 mg strength is sold under the brand name Proscar. Generic versions also exist. This page focuses on the hair-loss indication and does not address prostate treatment.
- Drug class: 5-alpha-reductase inhibitor, taken by mouth.
- Approved hair-loss indication in the U.S.: androgenetic alopecia in men.
- Approved hair-loss dose: 1 mg once daily.
- Other approved indication: benign prostatic hyperplasia at 5 mg once daily.
- Availability: prescription only, in 1 mg and 5 mg strengths, with generic versions available.
Sources: NCBI Bookshelf (StatPearls), International Society of Hair Restoration Surgery (ISHRS), GoodRx
How finasteride is thought to affect pattern hair loss
Finasteride works by competitively inhibiting the type II 5-alpha-reductase enzyme. This enzyme converts testosterone into dihydrotestosterone, or DHT. By blocking that conversion, finasteride lowers DHT levels in the body. The proposed link to pattern hair loss is that DHT is believed to suppress scalp follicles and miniaturize hair over time, so reducing DHT may slow the progression of androgenetic alopecia.
The measured effect on DHT is substantial. Finasteride reduces serum DHT by roughly 70 percent and prostatic DHT by upwards of 90 percent. Scalp DHT suppression has been measured in the range of about 43 percent at 28 days up to about 65 percent at 42 days in men with androgenetic alopecia taking finasteride 5 mg daily. The drug's elimination half-life in serum is roughly 5 to 6 hours in younger men and can be prolonged to around 8 hours in men over 70; DHT returns to normal within about 14 days after stopping.
- Target enzyme: type II 5-alpha-reductase.
- Effect: blocks conversion of testosterone to DHT.
- Serum DHT reduction: roughly 70 percent.
- Prostatic DHT reduction: upwards of 90 percent.
- DHT returns to baseline: within about 14 days after stopping.
Sources: NCBI Bookshelf (StatPearls), Drug Design, Development and Therapy (PMC / NCBI)
What research suggests about typical results and timelines
Research on finasteride for male pattern hair loss generally reports that a substantial share of men experience reduced loss, regrowth, or both, but results are not universal and benefits depend on continued use. In a widely cited 5-year study of men with mild to moderate male pattern hair loss, roughly 65 percent had a positive result, meaning reduced loss, regrowth, or both.
The evidence base also emphasizes that treatment takes time to assess. Continued treatment may need to be assessed over 6 to 12 months before benefit can be judged. If the medication is stopped, the gained and preserved hair is generally lost, because the underlying androgenetic process continues. Reported efficacy figures vary across sources and endpoints, so no single percentage captures the full picture.
| Measure | Reported figure | Context |
|---|---|---|
| Positive result in a 5-year study | Roughly 65% of men | Reduced loss and/or regrowth in men with mild to moderate male pattern hair loss |
| Progression stopped in some reports | Around 86% of men | Reported by a consumer advocacy source; not directly comparable to other figures |
| Substantial new hair growth in some reports | About 65% of trial participants | Reported by a consumer advocacy source; not directly comparable to other figures |
| Time to assess benefit | 6 to 12 months of continued treatment | Treatment benefit may not be judgeable before this range |
| Effect of stopping treatment | Gained and preserved hair generally lost | Continuing the drug is required to maintain benefit |
Sources: NCBI Bookshelf (StatPearls), International Society of Hair Restoration Surgery (ISHRS), American Hair Loss Association (AHLA), Journal of Investigative Dermatology Symposium Proceedings (Elsevier)
Reported side-effect categories and why monitoring matters
Finasteride's reported adverse-effect categories include sexual and non-sexual effects. Decreased libido, erectile dysfunction reported at roughly 2 to 4 percent, decreased ejaculatory volume, and gynecomastia are the categories most often listed. Orthostatic hypotension has also been reported, occurring in about 9 percent of monotherapy users and up to about 18 percent when combined with an alpha-blocker; the risk may be additive with alpha-blockers.
Reported rates are not uniform across studies. Some large studies show sexual side effects at placebo-comparable rates around 2.1 to 3.8 percent, while other studies report a subset of patients with persistent effects. Post-finasteride syndrome refers to adverse effects that may continue after discontinuing finasteride; its reported frequency and existence are contested in the literature, with some sources calling it rare and others describing ongoing investigation. Because finasteride lowers serum PSA, clinicians often adjust PSA interpretation; a median decrease of roughly 40 percent has been reported in men aged 40 to 49 and roughly 50 percent in men aged 50 to 60.
Monitoring matters because these categories include effects that a clinician can assess, because PSA interpretation may need adjustment during treatment, and because some symptoms may prompt a change in plan. Suspected adverse effects can be reported to the FDA at 1-800-FDA-1088.
- Decreased libido.
- Erectile dysfunction, reported at roughly 2 to 4 percent.
- Decreased ejaculatory volume.
- Gynecomastia.
- Orthostatic hypotension, with higher reported rates when combined with an alpha-blocker.
- PSA interpretation may need adjustment during treatment.
Sources: NCBI Bookshelf (StatPearls), International Society of Hair Restoration Surgery (ISHRS), Indian Journal of Dermatology, Venereology and Leprology (IADVL Therapeutic Guidelines), GoodRx
Why finasteride is prescription-only and requires clinician involvement
Finasteride is available by prescription only in the United States. Several characteristics make clinician involvement important. The drug and its dosing are indication-specific: 1 mg once daily for male pattern hair loss and 5 mg once daily for benign prostatic hyperplasia, so the correct product and strength depend on why it is being used. Reported adverse effects may need monitoring, and some, such as sexual side effects or orthostatic hypotension, may require discussion or a change in plan.
There are also population-specific cautions. Finasteride is labeled pregnancy category X and is contraindicated in women who are or may become pregnant because it can cause abnormal development of the external genitalia of a male fetus. Efficacy is not established for older adults, and the manufacturer does not establish safety and efficacy for pediatric patients. A clinician can weigh these factors, review current medications, and decide whether finasteride is appropriate for an individual. Nothing on this page is personalized medical advice.
Sources: NCBI Bookshelf (StatPearls), International Society of Hair Restoration Surgery (ISHRS), Indian Journal of Dermatology, Venereology and Leprology (IADVL Therapeutic Guidelines)
How finasteride compares conceptually with other treatment categories
Finasteride belongs to the prescription 5-alpha-reductase inhibitor category, which is distinct from topical treatments such as minoxidil that are applied directly to the scalp. The two are sometimes discussed together because they act in different ways and may be combined in selected patients by physician hair restoration specialists. Abrupt stoppage of either medication is usually followed by shedding of gained and preserved hair, so continuity matters for both.
Within the 5-alpha-reductase inhibitor category, finasteride and dutasteride differ in how broadly they inhibit the enzyme and in how long they remain in the body. Finasteride selectively inhibits type II and III 5-alpha-reductase and has a serum half-life of roughly 5 to 6 hours; dutasteride inhibits all three isoenzymes and has a half-life of roughly 4 to 5 weeks. Dutasteride has been reported to reduce serum DHT by about 99 percent. Neither finasteride nor dutasteride is FDA-approved for female pattern hair loss. In the United States, the only FDA-approved medication for female pattern hair loss is topical minoxidil.
| Attribute | Finasteride (oral, 1 mg) | Minoxidil (topical) | Dutasteride (oral) |
|---|---|---|---|
| Approved indication in the U.S. | Androgenetic alopecia in men | Described as the only FDA-approved agent for female pattern hair loss | Not FDA-approved for female pattern hair loss |
| Typical hair-loss dose | 1 mg once daily | Not stated in this guide | Not stated in this guide |
| Mechanism | Competitive type II 5-alpha-reductase inhibitor lowering testosterone-to-DHT conversion | Applied to the scalp; mechanism not detailed in this guide | Inhibits all three 5-alpha-reductase isoenzymes |
| Half-life | Roughly 5 to 6 hours | Not stated in this guide | Roughly 4 to 5 weeks |
| Serum DHT reduction | Roughly 70 percent | Not applicable to this comparison | About 99 percent reported |
| Use in women | Not FDA-approved for female pattern hair loss; contraindicated in women who are or may become pregnant | FDA-approved for female pattern hair loss | Not FDA-approved for female pattern hair loss |
Sources: NCBI Bookshelf (StatPearls), Drug Design, Development and Therapy (PMC / NCBI), International Society of Hair Restoration Surgery (ISHRS)
Frequently asked questions
Is finasteride effective for female pattern hair loss?
Some publications report positive results with finasteride for female pattern hair loss, but the evidence base and clinical efficacy remain limited and controversial. In the United States, finasteride is not FDA-approved for female pattern hair loss; use for that purpose would be off-label. It is contraindicated in women who are or may become pregnant because it can cause abnormal development of the external genitalia of a male fetus. The only FDA-approved medication for female pattern hair loss in the U.S. is topical minoxidil.
Sources: NCBI Bookshelf (StatPearls), Drug Design, Development and Therapy (PMC / NCBI), International Society of Hair Restoration Surgery (ISHRS), Indian Journal of Dermatology, Venereology and Leprology (IADVL Therapeutic Guidelines)How long before results may appear?
Continued treatment may need to be assessed over 6 to 12 months before benefit can be judged. If the medication is stopped, the gained and preserved hair is generally lost, so continued use is required to maintain benefit.
Sources: NCBI Bookshelf (StatPearls), International Society of Hair Restoration Surgery (ISHRS)Can finasteride be combined with minoxidil?
Finasteride is sometimes combined with minoxidil or surgical hair restoration in selected patients for an optimized result, according to professional-society patient information. This is a decision for a clinician, who can consider the individual's situation and the fact that abrupt stoppage of either medication is usually followed by shedding of gained and preserved hair.
Sources: International Society of Hair Restoration Surgery (ISHRS)What should I ask my clinician before starting finasteride?
Useful questions include whether the hair-loss pattern fits the approved indication, what dose and product strength are appropriate, how long to continue before judging benefit, what side-effect categories to watch for and how they would be managed, whether a PSA test is relevant for you and how finasteride might affect its interpretation, and whether any current medications or health conditions change the risk-benefit balance. Finasteride is contraindicated in women who are or may become pregnant, so pregnancy plans are also relevant.
Sources: NCBI Bookshelf (StatPearls), International Society of Hair Restoration Surgery (ISHRS), Indian Journal of Dermatology, Venereology and Leprology (IADVL Therapeutic Guidelines)Is finasteride the same as minoxidil?
No. Finasteride is an oral prescription 5-alpha-reductase inhibitor taken as a pill, while minoxidil is a topical product applied to the scalp. They act in different ways and are placed in different treatment categories. In the United States, finasteride is FDA-approved for androgenetic alopecia in men, and topical minoxidil is described as the only FDA-approved medication for female pattern hair loss.
Sources: NCBI Bookshelf (StatPearls), Drug Design, Development and Therapy (PMC / NCBI)What is post-finasteride syndrome?
Post-finasteride syndrome refers to adverse effects that may continue after discontinuing finasteride. Its reported frequency and existence are contested in the literature: some sources describe it as a recently reported issue with ongoing investigation, while others note that the frequency is controversial and that studies claiming persistence had limitations such as small sample sizes and bias. It should not be presented as a settled risk.
Sources: NCBI Bookshelf (StatPearls), International Society of Hair Restoration Surgery (ISHRS), Indian Journal of Dermatology, Venereology and Leprology (IADVL Therapeutic Guidelines)Why should men taking finasteride not donate blood?
Professional-society patient information advises that men taking finasteride should not donate blood, because the medication could be passed to a transfusion recipient. That guidance is especially relevant when a recipient could be pregnant. If you are taking finasteride and plan to donate blood, ask the blood collection center or your clinician for current guidance.
Sources: International Society of Hair Restoration Surgery (ISHRS)Can women handle finasteride tablets?
Professional-society patient information advises that finasteride should not be used or handled by a woman who is pregnant or who may become pregnant. This relates to the drug's potential to cause abnormal development of the external genitalia of a male fetus. Anyone with questions about safe handling should ask a pharmacist or clinician.
Sources: NCBI Bookshelf (StatPearls), International Society of Hair Restoration Surgery (ISHRS)Sources
- Finasteride - StatPearls - NCBI Bookshelf — NCBI Bookshelf (StatPearls)
- Finasteride and Its Potential for the Treatment of Female Pattern Hair Loss: Evidence to Date — Drug Design, Development and Therapy (PMC / NCBI)
- Finasteride: Doses, Side Effects & Uses for Hair Loss - ISHRS — International Society of Hair Restoration Surgery (ISHRS)
- Finasteride - American Hair Loss Association — American Hair Loss Association (AHLA)
- Use of Finasteride in the Treatment of Men With Androgenetic Alopecia (Male Pattern Hair Loss) — Journal of Investigative Dermatology Symposium Proceedings (Elsevier)
- Guidelines on the use of finasteride in androgenetic alopecia — Indian Journal of Dermatology, Venereology and Leprology (IADVL Therapeutic Guidelines)
- Finasteride (Propecia): Uses, Side Effects, Alternatives & More - GoodRx — GoodRx